52054 Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 

attitudes towards substance abuse. In 

order to test the effectiveness of the 

interactive multimedia module, data 

will be collected in the form of pre and 

post test surveys from 10th and 11th 

grade high school students utilizing the 

developed module. The findings will 

provide valuable information regarding 

information pertaining to the use of 

interactive multimedia educational 

modules in high school science 

classrooms and their ability to increase 

knowledge and change attitudes and 

perceptions. 

Frequency of Response: 4. Affected 

Public: High school students engaged 

with the ArchieMD: The Science of 

Drugs program. Type of Respondent: 

Participants will include high school 

students enrolled in the tenth and 

eleventh grade. Estimated Total Annual 

Number of Respondents: 360. Estimated 

Number of Responses per Respondent: 

4. Average Burden Hours per Response: 

One high school period lasting 50 

minutes. Estimated Total Annual 

Burden Hours Requested: 1199.95. 

There are no Capital Costs to report. 

There are no Operating or Maintenance 

Costs to report. The estimated 

annualized burden is summarized 

below. 

Type of respondents Number of 

respondents 

Frequency 

of response 

Average 

burden hours 

per response 

Estimated total 

burden hours 

requested 

Participants—High School Students ................................................................ 360 4 .8333 1199.95 

Total .......................................................................................................... 360 4 .8333 1199.95 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the functions of the 

agency, including whether the 

information shall have practical utility; 

(2) the accuracy of the agency’s estimate 

of the burden of the proposed collection 

of information; (3) ways to enhance the 

quality, utility, and clarity of the 

information to be collected; and (4) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 30-days of the date of 

this publication. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the information collection plans, please 

contact Dr. Cathrine Sasek, Coordinator, 

Science Education Program, Office of 

Science Policy and Communications, 

National Institute on Drug Abuse, 6001 

Executive Blvd, Room 5237, Bethesda, 

MD 20892, or call non-toll-free number 

(301) 443–6071; fax (301) 443–6277; or 

by e-mail to csasek@nida.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication. 

Dated: August 25, 2008. 

Mary Affeldt, 

Associate Director for Management, National 

Institute on Drug Abuse, National Institutes 

of Health. 

[FR Doc. E8–20778 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of federally 

funded research and development. 

Foreign patent applications are filed on 

selected inventions to extend market 

coverage for companies and may also be 

available for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301–

496–7057; fax: 301–402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Over-Expression and Mutation of a 

Tyrosine Kinase Receptor FGFR4 in 

Tumors 

Description of Technology: 

Rhabdomyosarcoma (RMS) is the most 

common type of pediatric soft tissue 

sarcoma. Most children (>70%) with the 

disease die at higher stage (metastatic 

disease). 

Researchers at NIH have identified 

mutations in fibroblast growth factor 

receptor 4 (FGFR4) that are associated 

with RMS tumors. It is proposed that 

individuals with FGFR4 mutations may 

have an increased risk for tumor 

metastasis. The identified FGFR4 

variants can be used to identify 

individuals who may benefit most from 

treatment with an FGFR4 inhibitor as an 

adjuvant to standard anticancer 

therapeutics to decrease the risk of 

tumor metastasis. 

Available for licensing are methods 

for identifying candidates for treatment 

with an inhibitor of FGFR4 by 

determining the presence of at least one 

FGFR4 variant, kits for identifying said 

candidates, and methods for identifying 

compounds that induce tumor cell 

death or that inhibit tumor growth or 

metastasis. 

Applications: 

• Potential new method for treatment 

of Rhabdomyosarcomas (RMS). 

• Potential new method to prepare 

kits to diagnose activating mutations in 

FGFR4. 

• These mutations can be used in 

laboratory settings to screen thousands 

of compounds for more specific FGFR4 

gene inhibitors. 

• FGFR4 is also a potential target for 

lung and breast cancer. 

• FGFR4 monoclonal can be 

developed to target RMS tumors. 

Market: 

• In the United States, approximately 

12,000 new cases of cancer are 

diagnosed in children each year. 

Childhood cancer remains the leading 

disease-related cause of death in 

children and adolescents in North 

America, with about 2,300 deaths each 

year. 

• Rhabdomyosarcoma accounts for 

about 3 percent of childhood cancers. In 

the U.S., about 350 children are 

diagnosed with Rhabdomyosarcoma 

each year. 

Development Status: Early-stage of 

development. 

Inventors: Javed Khan et al. (NCI). 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 52055 

Patent Status: U.S. Provisional 

Application No. 61/044,875 filed 14 Apr 

2008 (HHS Reference No. E–175–2008/ 

0–US–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Betty B. Tong, 

Ph.D.; 301–594–6565; 

tongb@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Pediatric 

Oncology Branch, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Over-expression and 

Mutation of a Tyrosine Kinase Receptor 

FGFR4 in Tumors. Please contact John 

D. Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Small Molecule Inhibitors of c-Met 

Description of Technology: Aberrant c 

Met signaling is documented in a wide 

variety of malignancies and occurs via 

several mechanisms including 

amplification of c-Met (increased gene 

copy number), point mutations in the 

gene encoding c-Met, receptor overexpression, and ligand dependent 

autocrine/paracrine receptor activation. 

This application describes novel small 

molecule inhibitors of c-Met signaling. 

The small molecules selectively bind to 

c-Met and have an IC50 in the 

micromolar range. The small molecules 

belong to two different families. One 

family of small molecules reduces the 

level of c Met expression via receptor 

down-regulation and blocks ATP 

binding. The other family of small 

molecules block ATP binding without 

inducing receptor down-regulation. 

Evidence suggests that the second 

family of compounds bind to both active 

and inactive conformations of c-Met. 

Applications: Therapy for cancers 

associated with aberrant c-Met 

signaling, for example bladder, breast, 

cervical, colorectal, endometrial, 

esophageal, gastric, head and neck, 

kidney, liver, lung, nasopharyngeal, 

ovarian, pancreatic, prostate and thyroid 

cancers, as well as cholangiocarconoma, 

osteosarcoma, rhabdomyosarcoma, 

synovial sarcoma, Kaposi’s sarcoma, 

leiomyosarcomas and MFH/ 

fibrosarcoma. In addition to these 

malignancies, aberrant c Met signaling 

is associated with hematological 

malignancies such as acute 

myelogenous leukemia, adult T cell 

leukemia, chronic myeloid leukemia, 

lymphomas and multiple myeloma as 

well as other tumors like melanoma, 

mesothelioma, Wilms’ tumor, 

glioblastomata and astrocytomas. 

Market: Although the percentage of 

cancers associated with aberrant c Met 

signaling is not yet well established, the 

wide variety of cancers associated with 

aberrant c Met signaling are indicative 

of a potentially large market for these 

compounds. For example, worldwide 

over 1 million persons per year are 

diagnosed with colorectal cancer and it 

is the most common gastrointestinal 

cancer in industrialized countries. In 

one study of colorectal cancer 69% of 

the patients had at least a two-fold 

elevation of cMet mRNA and 48% of the 

patients had at least a ten fold elevation 

of c Met mRNA. In a study of breast 

cancer, 22% of patients with invasive 

ductal breast tumor specimens exhibited 

strong expression of c Met and patients 

exhibiting c Met expression had only a 

52% 5 year survival rate compared with 

an 89% 5 year survival rate in patients 

with normal c Met levels. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Donald P. Bottaro, Terrence 

Burke, Jr., et al. (NCI). 

Patent Status: U.S. Provisional 

Application No. 61/041,523 filed 01 Apr 

2008 (HHS Reference No. E–332–2007/ 

0–US–01). 

Publications: The patent application 

has not been published. There are no 

journal articles available related to this 

work. 

Licensing Status: Available for 

licensing on an exclusive or nonexclusive basis. 

Licensing Contact: Susan S. Rucker; 

301–435–4478; 

Susan.Rucker@nih.hhs.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Urologic 

Oncology Branch, is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize small molecule 

inhibitors of the HGF/c-Met signaling 

pathway. Please contact John D. Hewes, 

Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Quantitative Immunoassays for 

Measurement of Topoisomerase I as a 

Pharmacodynamic Marker for the 

Effect of Anti-Cancer Drugs 

Description of Technology: 

Topoisomerase I (TopoI) is an enzyme 

that catalyses DNA unwinding which is 

necessary for many cellular functions. 

Recent data from the Fluorouracil, 

Oxaliplatin, CPT–11: Use and 

Sequencing (FOCUS) trial demonstrates 

that nuclear staining of TopoI correlates 

with chemotherapy efficacy [J Clin 

Oncol (2008) 26, 2690–8]. This enzyme 

covalently binds with the DNA substrate 

and introduces a single strand break. 

Some anti-cancer drugs, including those 

in clinical trials target this cleavage site 

and prevent re-ligation of the unwound 

DNA, trapping the TopoI/DNA covalent 

complex. TopoI trapped by Topo I 

inhibitor compounds such as Topotecan 

is degraded by the ubiquitin/proteosome 

pathway. This change in intracellular 

TopoI levels makes total TopoI and the 

TopoI/DNA covalent complex potential 

pharmacodynamic biomarkers for 

monitoring TopoI inhibiting agents, 

used in cancer therapy. 

The technology involves a validated, 

enzyme linked immunosorbent assay 

(ELISA) with a chemiluminescence 

readout, using commercially available 

antibodies to quantitate total TopoI from 

cell and tumor extracts. 

This technology has been used in a 

high throughput assay for measurement 

of estrogen and estrogen metabolites in 

serum. A similar ELISA assay has also 

been used in NCI Phase 0 and Phase I 

clinical trials of a PARP inhibitor 

Applications: 

• Anti-cancer drug testing. 

• Patient selection for anti-cancer 

drug treatment. 

Advantages: 

• Simple, quantitative, sensitive (LLQ 

∼40pg/well LLOD= (LOD 220 pg/ml as 

formulated), range 200 pg/ml to 50ng/ 

ml). 

• Uses commercially available 

antibodies. 

• Excludes the use of radioisotopes. 

• Validated Assay. 

• SOP available. 

• In vitro data support use in anticancer drug treated melanoma cell lines. 

• Mouse model data support use in 

anti-cancer drug treated melanoma and 

colon cancer xenografts. 

Developmental Status: ELISA was 

developed in support of Phase I clinical 

trial on experimental TopoI inhibiting 

drugs. 

Publication: Thomas D. Pfister, Ralph 

E. Parchment, Joseph Tomaszewski, 

James Doroshow and Robert J. Kinders. 

‘‘Development of a quantitative 

immunoassay for measurement of 

topoisomerase I covalent complex as a 

pharmacodynamic marker for the effect 

of anti-cancer drugs.’’ AACR Annual 

Meeting, Los Angeles, CA April 14–18, 

2007. 

Inventors: Thomas D. Pfister and 

Robert J. Kinders (SAIC/NCI). 

Patent Status: HHS Reference No. E–

100–2007/0—Research Tool. Patent 

protection is not being pursued for this 

technology. 

Licensing Status: Available for nonexclusive licensing of biological 

material. 

mstockstill on PROD1PC66 with NOTICES

52056 Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 

Licensing Contact: John Stansberry, 

Ph.D.; 301–435–5236; 

stansbej@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Laboratory of Human Toxicology and 

Pharmacology is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize Quantitative 

Immunoassays for Measurement of 

Topoisomerase I as a Pharmacodynamic 

Marker for the Effect of Anti-Cancer 

Drugs. Please contact John D. Hewes, 

Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

New Tumor Endothelial Markers: 

Genes That Distinguish Physiological 

and Pathological Angiogenesis 

Description of Technology: 

Angiogenesis, the formation of new 

blood vessels, is associated with normal 

physiological processes such as wound 

healing, ovulation or menstruation as 

well as with many diseases. Presently, 

it is thought to be required for the 

progressive growth of solid tumors and 

age-related macular degeneration. Lack 

of disease-specific endothelial markers 

has hindered the development of cancer 

therapies targeted against angiogenesis. 

This invention describes specific 

markers that can be used to identify 

tumor angiogenesis, separate from 

normal physiological angiogenesis. 

Several markers have been identified 

which may serve as potential targets for 

tumor vessels by using comparative 

gene expression analysis on various 

normal and tumor endothelial cells. 

Furthermore, the invention describes 

several organ-specific endothelial 

markers that can aid in the selective 

delivery of molecular medicine to 

specific sites. For example, brain 

endothelial markers (BEMs) and liver 

endothelial markers (LEMs) described 

herein could potentially be used to 

direct molecular medicine specifically 

to these tissues. 

The novel tumor endothelial markers 

(TEMs) described in this invention also 

have potential diagnostic ability. These 

markers can be used to distinguish 

between normal and tumor tissues. 

Some of the secreted TEMs can serve as 

surrogate markers in the determination 

of the optimum biological dose (OBD) 

for the current anti-angiogenic drugs in 

clinical trials. 

Applications and Modality: 

• Novel therapeutic targets associated 

with tumor vessels. 

• New agents can be developed 

against these novel targets. 

• Novel endothelial markers that 

distinguish pathological angiogenesis 

from normal physiological angiogenesis. 

• Surrogate tumor endothelial 

markers that can be used to determine 

optimal biological dose (OBD) of antiangiogenic drugs. 

Market: 

• Sales of the first FDA approved 

anti-angiogenic drug AvastinTM has 

reached $600 million. 

• Another promising anti-angiogenic 

molecule, ThalidomideTM, has been 

approved as an anti-cancer agent and for 

other use in Europe and Australia. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Brad St. Croix and Steven 

Seaman (NCI). 

Relevant Publication: A Nanda and B 

St. Croix. Tumor endothelial markers: 

new targets for cancer therapy. Curr 

Opin Oncol. 2004 Jan;16(1):44–49. 

Patent Status: 

• U.S. Provisional Application No. 

60/858,068 filed 09 Nov 2006 (HHS 

Reference No. E–285–2006/0–US–01). 

• U.S. Provisional Application No. 

60/879,457 filed 08 Jan 2007 (HHS 

Reference No. E–285–2006/1–US–01). 

• PCT Application No. PCT/US2007/ 

072395 filed 28 Jun 2007, which 

published as WO 2008/057632 on 15 

May 2008 (HHS Reference No. E–285–

2006/2–PCT–01). 

Licensing Status: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301–435–5560; 

madua@mail.nih.gov. 

Collaborative Research Opportunity: 

The NIH National Cancer Institute, 

Tumor Angiogenesis Section, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize specific biomarkers that 

can be used to identify tumor 

angiogenesis. Please contact John D. 

Hewes, PhD at 301/435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Methods of Treating and Preventing 

Renal Cancer Using a Dimethane 

Sulfonate Compound 

Description of Technology: Currently 

only a few small molecule inhibitors are 

effective in patients with renal cell 

carcinoma. Approximately 30,000 

patients per year are diagnosed with this 

disease but many of them are 

untreatable because of intrinsic drug 

resistance, and efficient drug transport 

and detoxification mechanisms. This 

invention described and claimed in the 

patent application describes a series of 

dimethane sulfonate compounds based 

on NSC 281612 that are suitable for the 

treatment of renal cancer. Compositions 

comprising a pharmaceuticallyacceptable carrier and a compound, or 

a salt suitable for use in the treatment 

or prevention of renal cancer are also 

described. The anti-tumor activity of 

NSC 281612 has been established in 

vivo against human renal tumor 

xenografts in mice. Suitable dosing and 

administration schedules for treatment 

of renal tumors have also been 

determined in this study. 

Applications: For treatment or 

prevention of renal cancer. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. Phase I clinical trials will 

begin this fall. 

Inventors: Susan D. Mertins, Susan E. 

Bates, David G. Covell, Geoffrey W. 

Patton, Melinda G. Hollingshead, B. Rao 

Vishnuvajjala (NCI). 

Patent Status: U.S. Patent Application 

No. 12/083,583 filed 14 Apr 2008, 

claiming priority to 14 Oct 2005 (HHS 

Reference No. E–249–2005/0–US–04). 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301–435–5560; 

madua@mail.nih.gov. 

Collaborative Research Opportunity: 

The National Cancer Institute, Screening 

Technologies Branch, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize biomarker assays for 

clinical utility (potential molecular 

targets have been identified). Please 

contact John D. Hewes, Ph.D. at 301–

435–3121 or hewesj@mail.nih.gov for 

more information. 

2-Amino-O4-Substituted Pteridines: 

Improved Chemotherapy Adjuvants 

Description of Technology: O6- 

Benzylguanine derivatives, some O6- 

benzylpyrimidines, and related 

compounds are known to be inactivators 

of the human DNA repair protein O6- 

alkylguanine-DNA alkyltransferase 

(alkyltransferase). This repair protein is 

the primary source of resistance many 

tumor cells develop when exposed to 

chemotherapeutic agents that modify 

the O6-position of DNA guanine 

residues. Therefore, inactivation of this 

protein can bring about a significant 

improvement in the therapeutic 

effectiveness of these chemotherapy 

drugs. The prototype inactivator O6- 

benzylguanine is currently in clinical 

trials in the United States as an adjuvant 

in combination with the 

chloroethylating agent 1, 3-bis (2- 

chloroethyl)-1-nitrosourea (BCNU) and 

the methylating agent temozolomide. A 

mstockstill on PROD1PC66 with NOTICES

Federal Register / Vol. 73, No. 174 / Monday, September 8, 2008 / Notices 52057 

similar alkyltransferase inactivator, O6- 

(4-bromothenyl) guanine is in clinical 

trials in the UK. 

This technology is directed to the 

discovery of a new class of potent 

alkyltransferase inactivators, 2-aminoO4-benzylpteridine derivatives targeted 

for use in cancer treatment in 

combination with chemotherapeutic 

agents such as 1, 3-bis (2-chloroethyl)- 

1-nitrosurea (BCNU) or temozolomide. 

The derivatives of the present invention 

inactivate the O6-alkylguanine-DNAalkyltransferase repair protein and thus 

enhance activity of such 

chemotherapeutic agents. Some of the 

derivatives are water soluble and 

possess tumor cell selectivity in 

particular by inactivating 

alkyltransferase in tumor cells that 

overexpress folic acid receptors. The 2- 

amino-O4-benzylpteridine derivatives 

represent a promising new class of 

alkyltransferase inactivator with 

representatives that may be great 

candidates as chemotherapy adjuvants. 

Applications and Modality: 

• New small molecules as 

alkyltransferase inactivators based on 2- 

amino-O4-benzylpteridine compounds. 

• Promising candidates as 

chemotherapy adjuvants for the 

treatment of cancer. 

• Therapeutic application for drug 

resistant tumors where acquired 

resistance is caused by O6-alkylguanineDNA alkyltransferase. 

Market: 

• 600,000 deaths from cancer related 

diseases estimated in 2006. 

• This technology involving small 

molecule therapeutics for the treatment 

of several cancers has a potential market 

of several billion U.S. dollars. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. 

Inventors: Robert C. Moschel (NCI) et 

al. 

Publication: ME Nelson, NA 

Loktionova, AE Pegg, RC Moschel. 2- 

amino-O4-benzylpteridine derivatives: 

Potent inactivators of O6-alkylguanineDNA alkyltransferase. J Med Chem. 

2004 Jul 15;47(15):3887–3891. 

Patent Status: 

• U.S. Patent Application No. 10/ 

585,566 filed 29 Aug 2006, claiming 

priority to 06 Jan 2004 (HHS Reference 

No. E–274–2003/0–US–03). 

• Foreign equivalents 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Adaku 

Nwachukwu, J.D.; 301–435–5560; 

madua@mail.nih.gov. 

Dated: August 26, 2008. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E8–20651 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel EARDA. 

Date: October 3, 2008. 

Time: 9 a.m. to 3 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, 4B01 CRMC, Rockville, 

MD 20852. 

Contact Person: Michele C. HindiAlexander, PhD, Division of Scientific 

Review, National Institutes of Health, Eunice 

Kennedy Shriver National Institute for Child 

Health & Development, 1600 Executive 

Boulevard, 5B01, Bethesda, MD 20812–7510, 

(301) 435–8382, hindialm@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: August 28, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–20644 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Eunice Kennedy Shriver National 

Institute of Child Health & Human 

Development; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Child Health and Human Development 

Special Emphasis Panel; The Role of Human 

Milk in Infant Nutrition and Health. 

Date: October 7, 2008. 

Time: 2 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6100 

Executive Boulevard, 5B01, Rockville, MD 

20852 (Telephone Conference Call). 

Contact Person: Rita Anand, PhD, 

Scientific Review Administrator, Division of 

Scientific Review, National Institute of Child 

Health and Human Development, NIH, 6100 

Executive Blvd, Room 5B01, Bethesda, MD 

20892, (301) 496–1487, 

anandr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.864, Population Research; 

93.865, Research for Mothers and Children; 

93.929, Center for Medical Rehabilitation 

Research; 93.209, Contraception and 

Infertility Loan Repayment Program, National 

Institutes of Health, HHS) 

Dated: August 28, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. E8–20646 Filed 9–5–08; 8:45 am] 

BILLING CODE 4140–01–P 

mstockstill on PROD1PC66 with NOTICES